Literature DB >> 16908528

Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression.

Wesley A Braden1, Jon M Lenihan, Zhengdao Lan, K Scott Luce, William Zagorski, Emily Bosco, Michael F Reed, Jeanette G Cook, Erik S Knudsen.   

Abstract

The retinoblastoma (RB) and p16ink4a tumor suppressors are believed to function in a linear pathway that is functionally inactivated in a large fraction of human cancers. Recent studies have shown that RB plays a critical role in regulating S phase as a means for suppressing aberrant proliferation and controlling genome stability. Here, we demonstrate a novel role for p16ink4a in replication control that is distinct from that of RB. Specifically, p16ink4a disrupts prereplication complex assembly by inhibiting mini-chromosome maintenance (MCM) protein loading in G1, while RB was found to disrupt replication in S phase through attenuation of PCNA function. This influence of p16ink4a on the prereplication complex was dependent on the presence of RB and the downregulation of cyclin-dependent kinase (CDK) activity. Strikingly, the inhibition of CDK2 activity was not sufficient to prevent the loading of MCM proteins onto chromatin, which supports a model wherein the composite action of multiple G1 CDK complexes regulates prereplication complex assembly. Additionally, p16ink4a attenuated the levels of the assembly factors Cdt1 and Cdc6. The enforced expression of these two licensing factors was sufficient to restore the assembly of the prereplication complex yet failed to promote S-phase progression due to the continued absence of PCNA function. Combined, these data reveal that RB and p16ink4a function through distinct pathways to inhibit the replication machinery and provide evidence that stepwise regulation of CDK activity interfaces with the replication machinery at two discrete execution points.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908528      PMCID: PMC1636881          DOI: 10.1128/MCB.00045-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  71 in total

Review 1.  CDK inhibitors: positive and negative regulators of G1-phase progression.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1999-06-15       Impact factor: 11.361

2.  ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex.

Authors:  S P Bell; B Stillman
Journal:  Nature       Date:  1992-05-14       Impact factor: 49.962

3.  pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F.

Authors:  Y P Chew; M Ellis; S Wilkie; S Mittnacht
Journal:  Oncogene       Date:  1998-10-29       Impact factor: 9.867

4.  Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7.

Authors:  J M Sterner; S Dew-Knight; C Musahl; S Kornbluth; J M Horowitz
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

5.  p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis.

Authors:  J Lukas; C S Sørensen; C Lukas; E Santoni-Rugiu; J Bartek
Journal:  Oncogene       Date:  1999-07-08       Impact factor: 9.867

6.  Phosphorylation-dependent binding of mitotic cyclins to Cdc6 contributes to DNA replication control.

Authors:  Satoru Mimura; Takashi Seki; Seiji Tanaka; John F X Diffley
Journal:  Nature       Date:  2004-10-20       Impact factor: 49.962

7.  Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression.

Authors:  H Jiang; H S Chou; L Zhu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.

Authors:  K E Knudsen; K C Arden; W K Cavenee
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

9.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

10.  Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.

Authors:  A A Russo; L Tong; J O Lee; P D Jeffrey; N P Pavletich
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

View more
  18 in total

1.  Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.

Authors:  Brian C Grieb; Mark W Gramling; Maria Pia Arrate; Xi Chen; Stephen L Beauparlant; Dale S Haines; Hua Xiao; Christine M Eischen
Journal:  Cancer Res       Date:  2014-05-01       Impact factor: 12.701

2.  Disruption of CDK-resistant chromatin association by pRB causes DNA damage, mitotic errors, and reduces Condensin II recruitment.

Authors:  Charles A Ishak; Courtney H Coschi; Michael V Roes; Frederick A Dick
Journal:  Cell Cycle       Date:  2017-07-19       Impact factor: 4.534

3.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Authors:  Eva Tonsing-Carter; Barbara J Bailey; M Reza Saadatzadeh; Jixin Ding; Haiyan Wang; Anthony L Sinn; Kacie M Peterman; Tiaishia K Spragins; Jayne M Silver; Alyssa A Sprouse; Taxiarchis M Georgiadis; T Zachary Gunter; Eric C Long; Robert E Minto; Christophe C Marchal; Christopher N Batuello; Ahmad R Safa; Helmut Hanenberg; Paul R Territo; George E Sandusky; Lindsey D Mayo; Christine M Eischen; Harlan E Shannon; Karen E Pollok
Journal:  Mol Cancer Ther       Date:  2015-10-22       Impact factor: 6.261

4.  The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Authors:  Sebastian Haferkamp; Sieu L Tran; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging (Albany NY)       Date:  2009-05-16       Impact factor: 5.682

5.  MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication.

Authors:  Debra L Evans; Haoxing Zhang; Hyoungjun Ham; Huadong Pei; SeungBaek Lee; JungJin Kim; Daniel D Billadeau; Zhenkun Lou
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

6.  Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication.

Authors:  Wasia Rizwani; Mark Alexandrow; Srikumar Chellappan
Journal:  Cell Cycle       Date:  2009-05-27       Impact factor: 4.534

7.  Cdt1 and Cdc6 are destabilized by rereplication-induced DNA damage.

Authors:  Jonathan R Hall; Hyun O Lee; Brandon D Bunker; Elizabeth S Dorn; Greg C Rogers; Robert J Duronio; Jeanette Gowen Cook
Journal:  J Biol Chem       Date:  2008-07-10       Impact factor: 5.157

8.  A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice.

Authors:  Rebecca Kinkade; Piyali Dasgupta; Adam Carie; Daniele Pernazza; Melanie Carless; Smitha Pillai; Nicholas Lawrence; Said M Sebti; Srikumar Chellappan
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

9.  Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell lines.

Authors:  Ryan J Bourgo; Wesley A Braden; Susanne I Wells; Erik S Knudsen
Journal:  Mol Carcinog       Date:  2009-01       Impact factor: 4.784

10.  Mammalian MCM loading in late-G(1) coincides with Rb hyperphosphorylation and the transition to post-transcriptional control of progression into S-phase.

Authors:  Piyali Mukherjee; Thinh V Cao; Sherry L Winter; Mark G Alexandrow
Journal:  PLoS One       Date:  2009-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.